Biochemical and biophysical research communicationsPoly(ADP-ribose) Polymerase InhibitorsXenograft Model Antitumor AssaysOvarian NeoplasmsTeratomaLoss of Heterozygosity
Genomic insights and therapeutic efficacy of PARP inhibitors in a high-LOH patient-derived xenograft from malignant transformation of ovarian teratoma.
Atsushi Nakagawa, Satoshi Tamauchi, Wang Xinyuan, Kosuke Yoshida, Akira Yokoi, Nobuhisa Yoshikawa, Kaoru Niimi, Hiroaki Kajiyama
Published: 202510.1016/j.bbrc.2025.152979
Abstract
The malignant transformation of ovarian mature cystic teratoma (MTMCT) is a rare and aggressive condition often diagnosed at advanced stages with limited treatment options. Leveraging cancer genomic profiling (CGP), this study evaluated the efficacy…
Preview only. Read the full abstract at the source